Health Economics›Acute myeloid leukemia pediatric›Consolidation after salvage therapy

Consolidation after salvage therapy

Acute myeloid leukemia pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cytarabine and Etoposide (CYVE) Variant #06	—	R 4 351	—	—	~9.2 mo	~2	~R 8 701 PFS proxy · indirect	—
Cytarabine and Thioguanine Variant #02	—	R 1 954	7d	—	—	~2	~R 3 908 indirect	—

2 of 2 regimens shown